Abstract:BACKGROUND: Transforming growth factor-β (TGF-β) is a major pro-fibrogenic cytokine that mediates the activation of hepatic stellate cells (HSC) and their over-production of extracellular matrix (ECM) components, the two key events during hepatic fibrogenesis. Signal transduction of TGF-β is initiated by binding of the ligand to TGF-β type II receptor (TGFβRII). The aim of this study is to reduce ECM production in rat HSC by knocking-down TGFβRII with RNA interference (RNAi) strategies. METHODS: Selected siRNA were transfected in a rat HSC line, SBC10, using TransIT TKO transfecting reagent. Real-time RT-PCR was used to determine mRNA levels of TGFβRII, procollagen type I (α1) (Procoll-I) and tissue inhibitor of metalloproteinase 1 (TIMP-1) in cells after siRNA or shRNA transfection. shRNA expression cassettes and lentiviral TGFβRII shRNA vectors containing the most effective siRNA sequences were generated to test their effects in SBC-10 cells. RESULTS: TGFβRII gene expression was reduced to 10.7 ± 4.5 % of controls with siRNAs at 50 nM 48 hrs after transfection. Moreover, mRNA levels of Procoll-I and TIMP-1 were reduced to 52.1 ± 6.6 % and 32.8 ± 5.2 % of controls 48 hrs after the siRNA transfection. Transfection of an shRNA expression cassette in SBC10 cells suppressed mRNA levels of TGFβRII, Procoll-I and TIMP-1 by 79%, 23% and 20%, 48 hours after transfection. The lentiviral TGFβRII shRNA vector transduction led to a 91-fold increase in shRNA production 5 days after transduction as indicated by real time RT-PCR, which resulted in a 69% reduction in TGFβRII mRNA levels, and 25–35% reduction in Procoll-I and TIMP-1 mRNA levels in the transduced cells. GFP expression in the lentiviral TGFβRII shRNA vector-transduced cells lasted for 21 days (the length of the experiment), with a transduction rate of 94.3%, as determined by flow cytometry. CONCLUSIONS: The findings demonstrated that the TGFβRII gene silencing by RNAi strategies inhibits fibrogenesis in rat HSCs. This novel approach may offer a new molecular therapy for hepatic fibrosis, for which effective treatment is not readily available. BACKGROUND: Transforming growth factor-β (TGF-β) is a major pro-fibrogenic cytokine that mediates the activation of hepatic stellate cells (HSC) and their over-production of extracellular matrix (ECM) components, the two key events during hepatic fibrogenesis. Signal transduction of TGF-β is initiated by binding of the ligand to TGF-β type II receptor (TGFβRII). The aim of this study is to reduce ECM production in rat HSC by knocking-down TGFβRII with RNA interference (RNAi) strategies. METHODS: Selected siRNA were transfected in a rat HSC line, SBC10, using TransIT TKO transfecting reagent. Real-time RT-PCR was used to determine mRNA levels of TGFβRII, procollagen type I (α1) (Procoll-I) and tissue inhibitor of metalloproteinase 1 (TIMP-1) in cells after siRNA or shRNA transfection. shRNA expression cassettes and lentiviral TGFβRII shRNA vectors containing the most effective siRNA sequences were generated to test their effects in SBC-10 cells. RESULTS: TGFβRII gene expression was reduced to 10.7 ± 4.5 % of controls with siRNAs at 50 nM 48 hrs after transfection. Moreover, mRNA levels of Procoll-I and TIMP-1 were reduced to 52.1 ± 6.6 % and 32.8 ± 5.2 % of controls 48 hrs after the siRNA transfection. Transfection of an shRNA expression cassette in SBC10 cells suppressed mRNA levels of TGFβRII, Procoll-I and TIMP-1 by 79%, 23% and 20%, 48 hours after transfection. The lentiviral TGFβRII shRNA vector transduction led to a 91-fold increase in shRNA production 5 days after transduction as indicated by real time RT-PCR, which resulted in a 69% reduction in TGFβRII mRNA levels, and 25–35% reduction in Procoll-I and TIMP-1 mRNA levels in the transduced cells. GFP expression in the lentiviral TGFβRII shRNA vector-transduced cells lasted for 21 days (the length of the experiment), with a transduction rate of 94.3%, as determined by flow cytometry. CONCLUSIONS: The findings demonstrated that the TGFβRII gene silencing by RNAi strategies inhibits fibrogenesis in rat HSCs. This novel approach may offer a new molecular therapy for hepatic fibrosis, for which effective treatment is not readily available.

Artificial MicroRNA-Mediated Tgfbr2 and Pdgfrb Co-Silencing Ameliorates Carbon Tetrachloride-Induced Hepatic Fibrosis in Mice

Liver Fibrosis Therapy Based on Biomimetic Nanoparticles Which Deplete Activated Hepatic Stellate Cells.

Targeting Transforming Growth Factor Βrii Expression Inhibits the Activation of Hepatic Stellate Cells and Reduces Collagen Synthesis

Effect of Shrna-Mediated Silencing of CTGF and TIMP-1 on Mrna Expression of CTGF, TIMP-1, and PCI and Secretion of Extracellular Matrix in Rat Hepatic Stellate Cells

RNA interfering connective tissue growth factor prevents rat hepatic stellate cell activation and extracellular matrix production.

Effects of RNA interference targeting transforming growth factor-beta 1 on immune hepatic fibrosis induced by Concanavalin A in mice.

MiR-542-3p controls hepatic stellate cell activation and fibrosis via targeting BMP-7.

Inhibition of Connective Tissue Growth Factor by Sirna Prevents Liver Fibrosis in Rats.

Mir-345–5P Curbs Hepatic Stellate Cell Activation and Liver Fibrosis Progression by Suppressing Hypoxia-Inducible Factor-1Alpha Expression

722. Silencing of Transforming Growth Factor-β Receptor II by RNA Interference Suppresses Extracellular Matrix Production in Rat Hepatic Stellate Cells

MicroRNA-30 Protects Against Carbon Tetrachloride-induced Liver Fibrosis by Attenuating Transforming Growth Factor Beta Signaling in Hepatic Stellate Cells

Targeting Tissue Inhibitor Of Metalloproteinase 1/2 Using A Shrna Lentiviral System Offers A Novel Treatment Strategy Against Hepatic Fibrosis

The Effect of Down-Regulation of Smad3 by RNAi on Hepatic Stellate Cells and a Carbon Tetrachloride-Induced Rat Model of Hepatic Fibrosis

MiR-22-3p and Mir-29A-3p Synergistically Inhibit Hepatic Stellate Cell Activation by Targeting AKT3

Inhibition of connective tissue growth factor suppresses hepatic stellate cell activation in vitro and prevents liver fibrosis in vivo

Targeting Follistatin like 1 ameliorates liver fibrosis induced by carbon tetrachloride through TGF-β1-miR29a in mice

Small Interfering RNA Targeting Connective Tissue Growth Factor Prevents Rats Liver Fibrosis

Effect of Small Interfering RNA Targeting Connective Tissue Growth Factor on the Synthesis and Secretion of Extracellular Matrix in Hepatic Stellate Cells

Effects of Sirna Targeting ADAMTS2 Gene on Hepatic Stellate Cells

Hepatic Stellate Cells Specific Liposomes With The Toll-Like Receptor 4 Shrna Attenuates Liver Fibrosis

Carbon Nitride‐Based siRNA Vectors with Self‐Produced O<sub>2</sub> Effects for Targeting Combination Therapy of Liver Fibrosis via HIF‐1α‐Mediated TGF‐β1/Smad Pathway